ADAR and neoplasm: First, target validation should integrate single-cell RNA-seq and spatial transcriptomics to map the expression of the enzyme (e.g. METTL3, ADAR1) across tumor and immune subsets within the tumor microenvironment (TME), ensuring tumor-specificity and identifying immune cell vulnerabilities [121].